Pharmacogenetics and pharmacogenomics;Pharmacogénétique et pharmacogénomique

Bulletin de l'Academie Nationale de Medecine

Volumn 190, Issue 1, 2006, Pages 9-23

  Bourel, Michel ^a   Ardaillou, Raymond ^a   Delaveau, Pierre ^b   Battin, Jacques ^b   Rochefort, Henri ^b   Tillement, Jean Paul ^b  

^a ACADÉMIE NATIONALE DE MÉDECINE   (France)

^b NONE

Author keywords

Clinical trials; Cytochrome P 450 enzyme system; Genomics; Metabolism; Oncogenes; Pharmaceutical pr parations; Pharmacogenetics; Polymorphism, genetics

Indexed keywords

EID: 33745781144     PISSN: 00014079     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0001-4079(19)33384-9     Document Type: Review

References (28)

1. QUENEAU P., BANWARTH B., CARPENTIER F., GULIANA J.M., BOUGET J., TROMBERT B., LEVERVE X. et l'APNET - Effets indésirables médicamenteux observés dans des Services d'Accueil et d'Urgences français (Etude prospective de l'APNET et propositions pour des mesures préventives). Bull. Acad. Natle Med., 2003, 187, 647-670.
2. KOHN L.T., CORRIGAN J.M., DONALDSON M.S. - To err is human- Building a safer health system. National Academy Press, 2000, Washington DC.
3. BEUTLER E. - Study of glucose-6-phoshate deshydrogenase: history and molecular biology. Am. J. Hematol., 1993, 42, 53-58.
4. SHI MM. - Enabling large-scale pharmacogenetic studies by high throughput mutation detection and genotyping technologies. Clin. Chem., 2001, 47, 164-172.
5. ALLORGE D., LORIOT M.A. - La pharmacogénétique ou la promesse d'une médecine personnalisée: variations du métabolisme et du transport des médicaments. Ann. Biol. Clin., 2004, 62, 499-511.
6. ILKINSON G.R. - Drug metabolism and variability among patients in drug response. New Engl. J. Med., 2005, 352, 2211-2221.
7. INGELMAN-SUNDBERG M. - Genetic polymorphisms of cytochrome P4502D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. The Pharmacogenomics J., 2005, 5, 6-13.
8. GASCHE Y., DAALI Y., FATHI M., CHIAPPE A., DAYER P., DESMEULES J. - Codeine intoxication associated with ultrarapid CYP2D6 metabolism. New Engl. J. Med., 2004, 351, 2867-2869.
9. KIRCHHEINER J., NICKCHEN K., BAUER M., WONG M.L., LICINIO J., ROOTS I., BROCKMOLLER J. - Pharmacogenetics of antidepressants and antipsychotics: the contribution of allelic variations to the phenotype of drug response. Mol. Psychiatry, 2004, 9, 442-473.
10. DERVIEUX T., MÉDARD Y., BAUDOUIN V., MAISIN A., ZHANG D., BROLY F., LOIRAT C., JACYZAIGRAIN E. - Thiopurine methyltransferase activity and its relationship to the occurence of rejection episodes in pediatric renal transplant recipients with azathioprine. Br. J. Clin. Pharmacol., 1999, 48, 780-800.
11. ANDO Y., SAKA H., ANDO M., SAWA T., MUHO K., UEOKA H., YAMAMOTO A., SAITOH S., SHIMOKATA K., HASEGAWA Y. - Polymorphisms of UDP- glucuronyltransferase gene and irinotecan toxicity: a pharmacogenetic analysis. Cancer Res., 2000, 60, 6921-6926.
12. HOFFMEYER S., BURK O., VON RICHTER O. - Functional polymorphisms of the human multidrug resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc. Natl. Acad. Sci. (USA), 2000, 97, 3473-3478.
13. VACHERON A. - Recommandations concernant les traitements anticoagulants par les antivitamines K. Bull. Acad. Natle Med., 2004, 188, 867-868.
14. GAGE B.F., EBY C.S. - The genetics of vitamin K antagonists. The Pharmacogenomics J., 2004, 4, 224-225.
15. BODIN L., VERSTUYFT C., TREGOUET D.A., ROBERT A., DUBERT L., FUNCK-BRENTANO C., JAILLON P., BEAUNE P., LAURENT-PUIG P., BECQUEMONT L., LORIOT M.A. - Cytochrome P4502C9 (CYP2C9) and vitamin K epoxide reductase (VKORC1) genotypes as determinants of acenocoumarol sensitivity. Blood, 2005, 106, 135-140.
16. WEI X., MCLEOD H.L., MCMURROUGH J., GONZALEZ F.J., FENANDEZ-SALGUERO P. - Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J. Clin. Invest, 1996, 98, 610-615.
17. ULRICH C.M., YASUI Y., STORB R., SCHUBERT M.M., WAGNER J.L., BIGLER J., ARIAIL K.S., KEENER C.L., LI S., LIU H., FARIN F.M., POTTER J.D. - Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood, 2001, 98, 231-234.
18. HETHERINGTON S., HUGUES A.R., MOSTELLER M., SHORTINO D., BAKER K.L., SPREEN W., LAI E., DAVIES K., HANDLEY A., Dow D.J., FLING M.E., STOCUM N., BOWMAN C., THURMOND L.M., ROSES A.D. - Genetic variations in HLA-B region and hypersensitivity to abacavir. Lancet, 2002, 359, 1121-1122.
19. STEARNS V., DAVIDSON N.E., FLOCKHART D.A. - Pharmacogenetics in the treatment of breast cancer. The Pharmacogenomics J., 2004, 4, 143-153.
20. KHALILI P., ARAKELIAN A., CHEN G., SINGH G., RABBANI S.A. - Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer. Oncogene, 2005, 24, 6657-6666.
21. HOSTEIN I., PELMUS M., AAURIAS A., PEDEUTOUR F., MATHOULIN-PELISSIER S., COINDRE J.M. - Evaluation of MDM2 and CDK4 amplification by real-time PCR on paraffin wax-embedded material: a potential tool for the diagnosis of atypical lipomatous tumours/well-differentiated liposarcomas. J. Pathol., 2004, 202, 95-102.
22. KHALILI P., ARAKELIAN A., CHEN G., SINGH G., RABBANI S.A. - Effect of Herceptin on the development and progression of skeletal metastases in a xenograft model of human breast cancer. Oncogene, 2005, en ligne dans PubMed.
23. MUKOHARA T., ENGELMAN J.A., HANNA N.H., YEAP B.Y., KOBAYASHI S., LINDEMAN N., HALMOS B., PEARLBERG J., TSUCHINASHI Z., CANTLEY L.C., TENEN D.G., JOHNSON B.E., JANNE P.A. - Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. Natl Cancer Inst., 2005, 97, 1185-1194.
24. BOUREL M., ARDAILLOU R. - Les centres de ressources biologiques dans les établissements de soins. Bull. Acad. Natle Med., 2002, 186, 1551-1564.
25. http://www.genemedrx.com
26. SMITS K.M., SCHOUTEN J.S., SMITS L.J., STELMA F.F., NELEMANS P., PRINS M.H. - A review on the design and reporting of studies on drug-gene interactions. J. Clin. Epidemiol. 2005, 58, 651-654.
27. Food and Drug Administration. Pharmacogenomic data submissions. En ligne dans http//:www.drugresearcher.com
28. Commission consultative nationale en matière d'examen des caractéristiques génétiques à des fins médicales. Rapport d'activité 200-2003. Ministère de la solidarité, de la santé et de la famille.